The Industry-Dedicated Forum, Focused on Novel Inflammasome Therapeutics
The 3rd Inflammasome Therapeutics Summit returns to unite a community dedicated to accelerating novel inflammasome-targeted drugs into the clinic!
Returning for its third year, the Inflammasome Therapeutics Summit is comprehensively addressing the industry’s key challenges of understanding the intricacies of inflammasome signaling to accelerate translation and clinical validation of novel inflammasome therapies!
The role of inflammasome signaling in disease and at the interface of innate immunity, neuroimmunity and metabolism, is constantly being elucidated. Meanwhile there continues to be ongoing innovation in the development of inflammasome therapies, with a plethora of drugs poised to enter early-stage clinical testing in 2021/22. As the clinical and commercial growth opportunity for inflammasome-targeted drugs becomes apparent, this meeting continues to be a center-points for exploring inflammasome-targeted strategies in monogenic diseases, as well as neurological, cancer, ophthalmic and inflammatory disorders.
From understanding different priming and activation signals for inflammasome formation to, to leveraging inflammasome proteins in precision-based medicine, exploring novel drug targets beyond NLRP3 and overcoming preclinical model challenges, this conference will delve into the clinical and commercial opportunities held by inflammasome-targeted therapies.
Alongside your peers, you can hear from and interact with 25+ thought leaders in our expert speaker faculty, have access to two parallel tracks of content exploring the latest advances in the inflammasome therapeutic field, form meaningful and long-lasting connections in the multiple and varied hybrid networking sessions built into the event.